Clinical Translation of Nanomedicine in Cancer Therapy
A special issue of Applied Sciences (ISSN 2076-3417). This special issue belongs to the section "Biomedical Engineering".
Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 930
Special Issue Editors
Interests: natural products; cell signaling; human health and disease; stem cell and regenerative medicine; bioinformatics
Special Issues, Collections and Topics in MDPI journals
Interests: cancer; nanomedicine; cell signalling; human health and disease
Interests: targeted therapeutic nanoparticles; neurological disorders; wound healing; cancer
2. King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia
3. Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, Dhaka 1207, Bangladesh
4. Enzymoics, 7 Peterlee Place, Hebersham, NSW 2770, Australia
5. Novel Global Community Educational Foundation, Hebersham, Australia
Interests: biochemistry; neuroscience; enzymology; toxicology; metabolomics; nanomedicines; manual lymph drainage and miRNA; leadership in managing staff performance and chaplaincy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Nanomedicine implies nanotechnologies for medical application with highly advanced medical intervention at molecular levels to cure diseases, especially cancer. It provides a platform for the discovery of therapeutic nanomaterials or nanomedicines. The growth in nanomedicines has introduced numerous new possibilities in terms of medical sciences, specifically in drug delivery.
- Their structural characteristics make them an excellent model for targeting specific sites and quick penetration inside the cell/ diseased sites.
- Depending on their application and origin, various types of nanoparticles have been discovered based on therapeutic needs. Liposomal, polymeric protein, metal-based, and iron oxide nanoparticles have emerged on top for cancer treatment.
- Achievements in the clinical translation of nanomedicines will not only improve therapeutic modalities for curing diseases but simultaneously will also bring down the costs involved.
- In a clinical scenario, several factors need to be addressed, viz. bioavailability, adverse reactions, cellular interactions, biodistribution, biodegradation, etc. The successful clinical translation of nanomedicines is expected to improve the diagnosis and therapeutic modalities for cancer significantly. However, the clinical translation of nanomedicine is limited due to the long onerous process involved and the inability to comprehensively assess their effect.
- This issue will introduce recent technological advances of nanoparticles, their types, applications in cancer, and related aspects.
Dr. Saurabh Kumar Jha
Dr. Ankur Sharma
Dr. Susan Hawthorne
Prof. Dr. Mohammad Amjad Kamal
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanomedicine
- drug delivery
- clinical translation
- cancer
- nanoparticles
- cell biology
